Invicta Diagnostic Limited IPO
Invicta Diagnostic Limited IPO
Invicta Diagnostic Limited IPO
₹ 272000 / 3200 Shares Shares
Minimum Investment
Invicta Diagnostic Limited IPO
Issues Price
₹80-85 per equity share
Invicta Diagnostic Limited IPO
Open Date
01 Dec 2025
Close Date
03 Dec 2025
Lot Size
1600
Min. Investment
₹ 272000
Issue Price
₹80-85
Listing Date
08 Dec 2025
Issues Size
33,08,800 shares(aggregating up to ₹28.12 crore)
Face Value
₹10 Per Equity Share
Total Shares Offered
3200 Shares
Offered To Public
3200 Shares
Invicta Diagnostic Limited IPO
Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions. It provides pathology and radiology testing comprising imaging, radiology, pathology, and teleradiology services under the brand 'PC Diagnostics” through 7 diagnostic centres and a central laboratory across Mumbai in Maharashtra. Invicta Diagnostics Limited, trading as PC Diagnostics, is a Mumbai-based diagnostic services company specializing in integrated pathology and radiology solutions. The company follows a hub‑and‑spoke model across the Mumbai Metropolitan Region, featuring: A flagship hub offering full-spectrum pathology and advanced radiology (CT, MRI) at Thane West Three other centres - Bhayandar, Byculla, Marol - offering specialized diagnostic services Basic imaging, including X-ray and ultrasound, and sample collection were the focus of spokes at Lower Parel, Sewri, Mazgaon, and Kalwa. It offers approximately 60 routine and 487 specialized pathology tests and around 96 basic and 130 advanced radiology investigations. Invicta Diagnostics provides a comprehensive suite of diagnostic services that includes: Routine Tests: Includes CBC, lipid profiles, liver function tests (LFT), kidney function tests (KFT), and thyroid panels Specialized Tests: Molecular diagnostics, immunoassays, infectious disease markers including dengue, COVID-19, cancer markers, and genetic panels. Sample Collection Network: Invicta uses phlebotomists and collection partners to reach patients at home or through its spoke centres. The company has a network of 5 laboratory doctors, 20 radiologists, and 127 well-trained technical staff as of May 31st, 2025. The company has 105 permanent employees as of May 31, 2025.
Founded In
2021
Managing Director
Dr. Ketan Jayantilal Jain
Parent Organization
Invicta Diagnostic Limited IPO
Application for Invicta Diagnostic Limited IPO
| Apply as | Price Range | Apply Upto |
|---|---|---|
| Individual (min) | ₹80-85 | ₹2,72,000 |
| Individual(max) | ₹80-85 | ₹2,72,000 |
| SHNI(min) | ₹80-85 | ₹4,08,000 |
| SHNI(max) | ₹80-85 | ₹9,52,000 |
| BHNI(min) | ₹80-85 | ₹10,88,000 |
Apply for all eligible candidates, Invicta Diagnostic Limited IPO.
Open On12 Dec 2025
Close On16 Dec 2025
Price Range₹2061-2165
Testimonial
Genuine Review Form Statisifed Customers
Living overseas, I struggled with Indian investments. KSquare’s NRI Corner fixed that. Their expert advice and ease of access gave me complete peace of mind.
KSquare’s approach to New Fund Offerings really impressed me. I finally feel confident participating in something I once thought was too complicated.
I use KSquare to manage my NRI investments. They provide clarity, legal compliance, and reliable support every step of the way. Excellent platform!
KSquare offers outstanding NFO briefings that help investors understand the market fit. They truly empower clients with knowledge before any commitment.
I've explored several NFOs through KSquare, and their consistent communication builds trust. It’s great having expert updates every step of the way.
I enrolled in NPS through KSquare and found their portal extremely intuitive. Their team guided me at every step.
I never imagined saving for the future could be this easy. KSquare’s SIP service is transparent, reliable, and perfect for professionals like me looking to invest smartly.
KSquare’s service was fast, transparent, and easy to follow. Perfect for someone like me who needed quick access to funds.
I’ve tested many platforms, but KSquare stands out for their transparency and consistent performance. SIPs with them feel like a smart, hassle-free decision.
KSquare stands out with their personalized approach to NRI investing. Their team’s insights and professionalism are unmatched.
FAQ's
Frequenlty Asked Question
Can NRIs get a loan against mutual funds with KSquare?
Some lenders allow NRIs to avail loans. KSquare helps identify NRI-eligible lenders and assists with documentation.
What happens if I stop my SIP before maturity?
You can withdraw your invested amount anytime. However, early exits might impact your long-term growth potential.
What is the minimum amount to start investing with KSquare?
NRIs can begin with as little as ₹1,000 per month depending on the investment vehicle, offering flexible entry points.
Which types of mutual funds are eligible for loans?
Typically, equity and debt mutual fund units held in demat form are eligible. KSquare helps confirm your fund’s eligibility instantly.
How do I manage taxes on my investments as an NRI?
KSquare provides tax guidance specific to NRIs, helping you plan and stay compliant with Indian tax laws.
Can I cancel or modify my NFO investment once submitted?
Yes, you can cancel or modify your NFO investment only before the allotment is processed and while the NFO is still open. Once the NFO closes and units are allotted, the investment cannot be changed or cancelled. After allotment, you may exit only through redemption, as per applicable terms and conditions.
Can I repatriate funds from my investments through KSquare?
Repatriation is allowed from NRE accounts. Investments via NRO are non-repatriable beyond set RBI limits.
Are mutual funds suitable for short-term goals?
Debt and liquid funds are ideal for short-term goals, while equity funds are better for long-term wealth creation.
Ksquare Timeline Pvt. Ltd. is an AMFI Registered Mutual Fund Distributor having ARN No. 146262. Mutual Fund investments are subject to market risks. Please read all scheme related documents carefully before investing. This website is intended only for informational and self-help purposes and should not be considered as investment advice or return guarantee. Past performance is not indicative of future results. Terms & Conditions apply.